PYC Therapeutics Ltd. is a drug-development company, which provides a new generation of RNA therapeutics to meet unmet need in disease. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2005-03-30. The firm utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002). The firm's VP-001 program is a lead asset for a blinding eye disease of childhood progressed through multiple patient cohorts in the ongoing single ascending dose clinical trial. ADOA is a progressive and blinding eye disease.
Follow-Up Questions
PYC Therapeutics Ltd 'in CEO'su kimdir?
Dr. Rohan Hockings 2016 'den beri şirketle birlikte olan PYC Therapeutics Ltd 'in Chief Executive Officer 'ıdır.
PYCXF hissesinin fiyat performansı nasıl?
PYCXF 'in mevcut fiyatı $0 'dir, son işlem günde 0% decreased etti.
PYC Therapeutics Ltd için ana iş temaları veya sektörler nelerdir?
PYC Therapeutics Ltd Biotechnology endüstrisine ait ve sektör Health Care 'dir
PYC Therapeutics Ltd 'in mevcut piyasa değerlemesi $0 'dir
PYC Therapeutics Ltd al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 7 analist PYC Therapeutics Ltd için analist derecelendirmeleri gerçekleştirdi, bunlar 1 güçlü al, 8 al, 1 tut, 0 sat ve 1 güçlü sat içermektedir
